Search
for
Sort by
Research 30 of 1000+
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
- Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Management of Toxicities of Targeted Therapies
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment.
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Persistent hair growth during treatment with the EGFR inhibitor erlotinib
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Dermatologic Reactions to Targeted Therapy
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- The PDGF/PDGFR pathway as a drug target
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series
- Dacomitinib-Induced Paronychia Associated With PRIDE Syndrome in a Patient With Non-Small Cell Lung Cancer